Orchard Therapeutics
Orchard Therapeutics is a leading global fully integrated commercial stage company dedicated to transforming the lives of patients with rare diseases through innovative gene therapies. Orchard is privately-held. In its latest, Series B funding round (Dec 2017), the company raised $110M. Orchard was named a Fierce 15 Company by FierceBiotech in 2016.
